Royalty Pharma PE ratio RPRX

Share price divided by earnings per share over the last twelve months, since 2021.

Today, Oct 23, 2026: 36.3×
6-year median: 20.4×
Against its 6-year history: 99th; percentile: 0 is its lowest day, 100 its highest
6-year range: 10.9× to 36.3×
Peer median: 39.4×

Royalty Pharma's PE ratio is 36.3× as of Oct 23, 2026: a share price of $63.86 against $1.76 of earnings per share over the last twelve months.

That is above its 6-year median of 20.4×, higher than on 99% of days in the last 6 years.

Over that time it ranged from 10.9× in Dec 2024 to 36.3× in Sep 2026.

The median for 10 healthcare stocks of a similar size is 39.4×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	36.3×	23.7×	36.3×
2025	23.9×	11.3×	24.4×
2024	11.2×	10.9×	23.6×
2023	n/m a value too high to mean anything
2022	22.1×	19.8×	22.8×
2021	20.6×	14.3×	35.8×

Against its peers

Companies in Healthcare nearest Royalty Pharma's size, closest first, today.

Company	PE ratio
RPRXRoyalty Pharma	36.3×
RMDResMed	24.2×
BIIBBiogen	44.4×
CNCCentene	n/m
ZTSZoetis	13.3×
MTDMettler-Toledo International	37.6×
ILMNIllumina	50.1×
GEHCGE HealthCare Technologies	16.4×
ONCBeOne Medicines	67.6×
IDXXIDEXX Laboratories	39.4×
WATWaters	113×
Peer median	39.4×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Royalty Pharma

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.